Prevention and management of infections in patients undergoing CAR T-cell therapy : Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved..
Infections occurring after CAR T-cells are a common complication. At the acute phase of treatment following CAR T-cell infusion, the exact incidence of infections is unknown given the overlapping symptoms with cytokine release syndrome. The risk factors for infection include the malignant underlying disease and its multiple treatments, and an immunosuppressive state induced by CAR-T cells themselves and the treatment of their complications. During the twelfth edition of practice harmonization workshops of the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC), a working group focused its work on the management of post-CAR infectious complications. In this review we discuss anti-infection prophylaxis and vaccination of patients undergoing CAR T-cell therapy as well as a special chapter for the specific case of COVID-19. These recommendations apply to commercial CAR-T cells, in order to guide strategies for the management and prevention of infectious complications associated with this new therapeutic approach.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:108 |
|---|---|
| Enthalten in: |
Bulletin du cancer - 108(2021), 12S vom: 15. Dez., Seite S90-S97 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Prise en charge prophylactique, thérapeutique des complications infectieuses et vaccination des patients traités par CAR-T cells : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) |
|---|
| Beteiligte Personen: |
Paul, Franciane [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CAR T-cell therapy |
|---|
| Anmerkungen: |
Date Completed 29.12.2021 Date Revised 29.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bulcan.2021.11.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334129036 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334129036 | ||
| 003 | DE-627 | ||
| 005 | 20231225223047.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.bulcan.2021.11.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM334129036 | ||
| 035 | |a (NLM)34876272 | ||
| 035 | |a (PII)S0007-4551(21)00446-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Paul, Franciane |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevention and management of infections in patients undergoing CAR T-cell therapy |b Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) |
| 246 | 3 | 3 | |a Prise en charge prophylactique, thérapeutique des complications infectieuses et vaccination des patients traités par CAR-T cells : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.12.2021 | ||
| 500 | |a Date Revised 29.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Infections occurring after CAR T-cells are a common complication. At the acute phase of treatment following CAR T-cell infusion, the exact incidence of infections is unknown given the overlapping symptoms with cytokine release syndrome. The risk factors for infection include the malignant underlying disease and its multiple treatments, and an immunosuppressive state induced by CAR-T cells themselves and the treatment of their complications. During the twelfth edition of practice harmonization workshops of the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC), a working group focused its work on the management of post-CAR infectious complications. In this review we discuss anti-infection prophylaxis and vaccination of patients undergoing CAR T-cell therapy as well as a special chapter for the specific case of COVID-19. These recommendations apply to commercial CAR-T cells, in order to guide strategies for the management and prevention of infectious complications associated with this new therapeutic approach | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CAR T-cell therapy | |
| 650 | 4 | |a CAR-T cells | |
| 650 | 4 | |a Infections | |
| 650 | 4 | |a Prophylaxie | |
| 650 | 4 | |a Prophylaxis | |
| 650 | 4 | |a Vaccination | |
| 650 | 7 | |a Immunoglobulins |2 NLM | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 700 | 1 | |a Vicente, Céline |e verfasserin |4 aut | |
| 700 | 1 | |a Courbon, Corinne |e verfasserin |4 aut | |
| 700 | 1 | |a Moreau, Anne-Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Picard, Muriel |e verfasserin |4 aut | |
| 700 | 1 | |a Pochon, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Sterin, Arthur |e verfasserin |4 aut | |
| 700 | 1 | |a Tudesq, Jean-Jacques |e verfasserin |4 aut | |
| 700 | 1 | |a Yakoub-Agha, Mathilde |e verfasserin |4 aut | |
| 700 | 1 | |a Bay, Jacques-Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Yakoub-Agha, Ibrahim |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin du cancer |d 1966 |g 108(2021), 12S vom: 15. Dez., Seite S90-S97 |w (DE-627)NLM000155853 |x 1769-6917 |7 nnns |
| 773 | 1 | 8 | |g volume:108 |g year:2021 |g number:12S |g day:15 |g month:12 |g pages:S90-S97 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bulcan.2021.11.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 108 |j 2021 |e 12S |b 15 |c 12 |h S90-S97 | ||